| D007122 |
Immunoelectrophoresis |
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera. |
|
|
| D009103 |
Multiple Sclerosis |
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) |
MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple |
|
| D001798 |
Blood Proteins |
Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. |
Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum |
|
| D002556 |
Cerebrospinal Fluid Proteins |
Proteins in the cerebrospinal fluid, normally albumin and globulin present in the ratio of 8 to 1. Increases in protein levels are of diagnostic value in neurological diseases. (Brain and Bannister's Clinical Neurology, 7th ed, p221) |
Proteins, Cerebrospinal Fluid,Fluid Proteins, Cerebrospinal |
|
| D004355 |
Drug Stability |
The chemical and physical integrity of a pharmaceutical product. |
Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs |
|
| D004587 |
Electrophoresis, Agar Gel |
Electrophoresis in which agar or agarose gel is used as the diffusion medium. |
Electrophoresis, Agarose Gel,Agar Gel Electrophoresis,Agarose Gel Electrophoresis,Gel Electrophoresis, Agar,Gel Electrophoresis, Agarose |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D013344 |
Subacute Sclerosing Panencephalitis |
A rare, slowly progressive encephalitis caused by chronic infection with the MEASLES VIRUS. The condition occurs primarily in children and young adults, approximately 2-8 years after the initial infection. A gradual decline in intellectual abilities and behavioral alterations are followed by progressive MYOCLONUS; MUSCLE SPASTICITY; SEIZURES; DEMENTIA; autonomic dysfunction; and ATAXIA. DEATH usually occurs 1-3 years after disease onset. Pathologic features include perivascular cuffing, eosinophilic cytoplasmic inclusions, neurophagia, and fibrous gliosis. It is caused by the SSPE virus, which is a defective variant of MEASLES VIRUS. (From Adams et al., Principles of Neurology, 6th ed, pp767-8) |
Encephalitis, Inclusion Body, Measles,Leukoencephalitis, Subacute Sclerosing,Measles Inclusion Body Encephalitis,Panencephalitis, Subacute Sclerosing,SSPE,Van Bogaert's Leukoencephalitis,Inclusion Body Encephalitis, Measles,Leukoencephalitis, Van Bogaert's,Sclerosing Leukoencephalitis, Subacute,Sclerosing Panencephalitis, Subacute,Leukoencephalitides, Subacute Sclerosing,Leukoencephalitis, Van Bogaert,Leukoencephalitis, Van Bogaerts,Panencephalitides, Subacute Sclerosing,Sclerosing Leukoencephalitides, Subacute,Sclerosing Panencephalitides, Subacute,Subacute Sclerosing Leukoencephalitides,Subacute Sclerosing Leukoencephalitis,Subacute Sclerosing Panencephalitides,Van Bogaert Leukoencephalitis,Van Bogaerts Leukoencephalitis |
|